Improving the Accuracy of Bone-Scintigraphy Imaging Analysis Using the Skeletal Count Index: A Study Based on Human Trial Data
Radiation,
Год журнала:
2025,
Номер
5(1), С. 5 - 5
Опубликована: Янв. 17, 2025
The
image
quality
index
for
whole-body
bone
scintigraphy
has
traditionally
relied
on
the
total
count
(Total-C)
with
a
threshold
of
≥1.5
million
counts
(MC).
However,
Total-C
measurements
are
susceptible
to
variability
owing
urine
retention.
This
study
aimed
develop
skeletal
(Skel-C)-based
index,
focusing
exclusively
regions,
improve
accuracy
analysis
in
scintigraphy.
To
determine
optimal
Skel-C-based
threshold,
Skel-C
thresholds
were
set
at
0.9,
1.0,
1.1,
and
1.2
MC,
1.75,
2.0,
2.25
MC.
Patients
then
categorized
based
whether
their
values
above
or
below
these
thresholds.
group
including
all
cases
was
defined
as
1.5
high
group.
Sensitivity
specificity
calculated
each
group,
receiver
operating
characteristic
analyses
statistical
evaluations
conducted.
program
<
0.9
MC
significantly
lower
than
that
≥
groups.
decrease
evident
only
not
identified
levels.
These
findings
highlight
importance
achieving
suggest
alone
is
insufficient
reliable
assessment.
Язык: Английский
Postmarketing safety of [ 177 Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system
Expert Opinion on Drug Safety,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 11, 2025
[177Lu]Lu-PSMA-617
(Pluvicto),
a
new
radioligand
therapy
that
targets
prostate-specific
membrane
antigen
(PSMA),
has
been
approved
to
treat
metastatic
castration-resistant
prostate
cancer
(mCRPC).
However,
the
real-world
safety
profile
of
not
systemically
evaluated.
Adverse
event
reports
for
were
retrieved
from
April
2022
June
2024
The
Food
and
Drug
Administration
Event
Reporting
System
(FAERS)
database.
Disproportionality
analysis
was
conducted
by
four
algorithms:
reporting
odds
ratio
(ROR),
proportional
(PRR),
Multi-Item
Gamma
Poisson
Shrinker
(MGPS)
Bayesian
Confidence
Propagation
Neural
Network
(BCPNN).
Subgroup
analysis,
time-to-onset
sensitivity
also
employed.
384,2712
adverse
retrieved,
which
870
associated
with
in
patients.
We
identified
known
events
(fatigue/asthenia,
anemia,
thrombocytopenia
nausea)
discovered
specified
on
label
(loss
libido,
hydronephrosis,
supraventricular
tachycardia,
tumor
lysis
syndrome,
flare).
revealed
high-risk
signals
included
stomatitis,
pneumonia,
leukopenia,
sepsis
patients
aged
over
85.
median
onset
time
55
days
(interquartile
range
24-124
days).
findings
provide
insights
into
valuable
references
clinical
applications
mCRPC.
Язык: Английский